[go: up one dir, main page]

BR9910504A - Agonistas e antagonistas seletivos de il-2 - Google Patents

Agonistas e antagonistas seletivos de il-2

Info

Publication number
BR9910504A
BR9910504A BR9910504-7A BR9910504A BR9910504A BR 9910504 A BR9910504 A BR 9910504A BR 9910504 A BR9910504 A BR 9910504A BR 9910504 A BR9910504 A BR 9910504A
Authority
BR
Brazil
Prior art keywords
antagonists
muteins
cells
human
agonists
Prior art date
Application number
BR9910504-7A
Other languages
English (en)
Other versions
BRPI9910504B1 (pt
Inventor
Armen B Shanafelt
Jeffrey M Greve
Gary Jesmok
Kenneth J Lembach
Gayle D Wetzel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9910504A publication Critical patent/BR9910504A/pt
Publication of BRPI9910504B1 publication Critical patent/BRPI9910504B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Patente de Invenção: <B>"AGONISTAS E ANTAGONISTAS SELETIVOS DE IL-2"<D>. A invenção é direcionada a um polipeptídeo compreendendo uma muteína de IL-2 humana numerada de acordo com a IL-2 do tipo silvestre onde a referida IL-2 humana é substituída em pelo menos uma das posições 20, 88 ou 126, por meio das quais a referida muteína preferivelmente ativa as células T sobre as células NK. D20H e I. N88G, I e R, em particular têm uma atividade diferencial de célula T relativa, muito maior do que a IL-2 nativa, com predita toxidade in vivo reduzida associada. A invenção também inclui polinucleotídeos codificando para as muteínas da invenção, vetores contendo os polinucleotídeos, células hospedeiras transformadas, composições farmacêuticas compreendendo as muteínas e métodos terapêuticos de tratamento.
BRPI9910504A 1998-05-15 1999-05-13 polipeptídeos agonistas e antagonistas seletivos de il-2, polinucleotideos que os codificam, composição farmacêutica contendo os referidos polipeptídeos, vetor e célula hospedeira BRPI9910504B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
PCT/US1999/010643 WO1999060128A1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (2)

Publication Number Publication Date
BR9910504A true BR9910504A (pt) 2001-01-09
BRPI9910504B1 BRPI9910504B1 (pt) 2016-08-09

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9910504A BRPI9910504B1 (pt) 1998-05-15 1999-05-13 polipeptídeos agonistas e antagonistas seletivos de il-2, polinucleotideos que os codificam, composição farmacêutica contendo os referidos polipeptídeos, vetor e célula hospedeira

Country Status (39)

Country Link
EP (1) EP1076704B1 (pt)
JP (1) JP4276783B2 (pt)
KR (1) KR100607609B1 (pt)
CN (2) CN100366742C (pt)
AR (1) AR020322A1 (pt)
AT (1) ATE351907T1 (pt)
AU (1) AU759697B2 (pt)
BG (1) BG65139B1 (pt)
BR (1) BRPI9910504B1 (pt)
CA (1) CA2327349C (pt)
CO (1) CO5070701A1 (pt)
CU (2) CU23273B7 (pt)
CY (1) CY1107533T1 (pt)
CZ (1) CZ302071B6 (pt)
DE (1) DE69934881T2 (pt)
DK (1) DK1076704T3 (pt)
DZ (1) DZ2788A1 (pt)
ES (1) ES2281175T3 (pt)
HK (1) HK1039963B (pt)
HN (1) HN1999000075A (pt)
HU (1) HU226142B1 (pt)
IL (2) IL139136A0 (pt)
MY (1) MY130274A (pt)
NO (1) NO329235B1 (pt)
NZ (1) NZ508098A (pt)
PA (1) PA8472601A1 (pt)
PE (1) PE20000475A1 (pt)
PL (1) PL201675B1 (pt)
PT (1) PT1076704E (pt)
RO (1) RO122150B1 (pt)
RU (1) RU2235729C2 (pt)
SI (1) SI20643B (pt)
SK (1) SK288100B6 (pt)
SV (1) SV1999000061A (pt)
TN (1) TNSN99090A1 (pt)
TR (1) TR200003354T2 (pt)
TW (1) TWI223663B (pt)
UA (1) UA73719C2 (pt)
WO (1) WO1999060128A1 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267215T1 (de) 1997-12-08 2004-06-15 Lexigen Pharm Corp Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US6566500B1 (en) 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA03009924A (es) 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
KR101403910B1 (ko) 2003-11-04 2014-06-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법
EP1718670B1 (en) * 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
ES2694564T3 (es) 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
EA201992609A1 (ru) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017281469B2 (en) 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
US10472405B2 (en) * 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN111107868A (zh) * 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
SG11202000939PA (en) * 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
PH12020550661A1 (en) * 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR102722731B1 (ko) 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
CN120590539A (zh) 2018-03-28 2025-09-05 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
KR20210038549A (ko) * 2018-07-24 2021-04-07 비온테크 알엔에이 파마슈티컬스 게엠베하 Il2 작용제
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR102201086B1 (ko) * 2018-09-17 2021-01-11 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
AU2019343251B2 (en) 2018-09-21 2022-06-09 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
TW202034945A (zh) 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素２變體或其衍生物
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
MX2022001061A (es) 2019-07-26 2022-02-14 Visterra Inc Agentes de interleuquina-2 y usos de los mismos.
UY38836A (es) * 2019-08-13 2021-02-26 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
US20230036793A1 (en) 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs
BR112022011949A2 (pt) 2019-12-17 2022-11-22 Amgen Inc Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物
IL294070A (en) * 2020-01-14 2022-08-01 Synthekine Inc Il2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115698052A (zh) 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
KR102545250B1 (ko) * 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
JP2023527919A (ja) 2020-06-03 2023-06-30 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２配列及びその使用
EP4236962A1 (en) 2020-10-29 2023-09-06 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
MX2024003535A (es) 2021-09-22 2024-05-07 Fortvita Biologics Singapore Pte Ltd Proteina mutante de interleucina-2 y fusion de la misma.
JP2024533848A (ja) 2021-10-06 2024-09-12 イルトゥー・ファルマ 炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
AU2023295521A1 (en) * 2022-06-16 2025-01-02 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
FR3140287B1 (fr) 2022-10-03 2025-11-21 Arkema France Procede de granulation de composes azoiques et granules obtenus
EP4631972A1 (en) 2022-11-18 2025-10-15 Nanjing Novoacine Biotechnology Co., Ltd. Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003334C1 (ru) * 1988-07-26 1993-11-30 Хем Рисерч, Инк, (US) Способ лечени больных с опухол ми
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
EP1076704A1 (en) 2001-02-21
SK17242000A3 (sk) 2001-07-10
PL344407A1 (en) 2001-11-05
PE20000475A1 (es) 2000-07-07
CA2327349C (en) 2010-10-26
WO1999060128A1 (en) 1999-11-25
SV1999000061A (es) 2000-03-14
AR020322A1 (es) 2002-05-08
PL201675B1 (pl) 2009-04-30
CN101319247B (zh) 2012-12-12
DZ2788A1 (fr) 2003-12-01
PA8472601A1 (es) 2000-09-29
PT1076704E (pt) 2007-02-28
IL139136A0 (en) 2001-11-25
CN100366742C (zh) 2008-02-06
BG65139B1 (bg) 2007-03-30
ES2281175T3 (es) 2007-09-16
CZ20004213A3 (en) 2001-05-16
HN1999000075A (es) 1999-09-29
UA73719C2 (en) 2005-09-15
JP4276783B2 (ja) 2009-06-10
DE69934881D1 (de) 2007-03-08
EP1076704B1 (en) 2007-01-17
RO122150B1 (ro) 2009-01-30
IL139136A (en) 2009-05-04
NO20005762D0 (no) 2000-11-14
KR100607609B1 (ko) 2006-08-02
HUP0101948A3 (en) 2003-08-28
NO329235B1 (no) 2010-09-20
HUP0101948A2 (hu) 2001-09-28
NZ508098A (en) 2003-09-26
CN1309705A (zh) 2001-08-22
JP2002515247A (ja) 2002-05-28
CU23272A1 (es) 2008-04-09
CN101319247A (zh) 2008-12-10
CZ302071B6 (cs) 2010-09-29
HU226142B1 (en) 2008-05-28
SI20643A (sl) 2002-02-28
CA2327349A1 (en) 1999-11-25
BRPI9910504B1 (pt) 2016-08-09
RU2235729C2 (ru) 2004-09-10
HK1039963B (zh) 2008-09-05
BG104929A (en) 2001-09-28
CO5070701A1 (es) 2001-08-28
AU759697B2 (en) 2003-04-17
TNSN99090A1 (fr) 2005-11-10
KR20010043602A (ko) 2001-05-25
MY130274A (en) 2007-06-29
TR200003354T2 (tr) 2001-03-21
SK288100B6 (sk) 2013-07-02
NO20005762L (no) 2001-01-11
CY1107533T1 (el) 2013-03-13
ATE351907T1 (de) 2007-02-15
SI20643B (sl) 2008-02-29
TWI223663B (en) 2004-11-11
DK1076704T3 (da) 2007-03-12
DE69934881T2 (de) 2007-11-08
CU23273B7 (es) 2008-04-09
HK1039963A1 (zh) 2002-05-17
AU4078499A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
BR9910504A (pt) Agonistas e antagonistas seletivos de il-2
Sreter et al. The effect of cross reinnervation on the synthesis of myosin light chains
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
BR0108025A (pt) Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase
DK0409472T3 (da) Knoglemorfogenetisk protein
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
SE8102194L (sv) Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
ES8609279A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,2,3-triazol.
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
NO931141L (no) Tnf-muteiner
DK0579640T3 (da) Glialmitogene faktorer samt deres fremstilling og anvendelse
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
ATE203240T1 (de) Heterocyclische diarylverbindungen, sie enthaltende pharmazeutische und kosmetische zusammensetzungen, und ihre verwendung.
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
DK0902085T3 (da) Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
BRPI0410470A (pt) uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
BR9910585A (pt) Promotor de bmp-7 humano e método para explorar substância relacionada com os ossos usando o mesmo
DE69533796D1 (de) Für die glutamatabhängigen chloridkanäle kodierende dna
EA008938B1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
NO915084L (no) Fremgangsmaate ved fremstilling av human interleukin-5 receptor
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER CORPORATION

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090023404/RJ DE 11/03/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.